(February 20, 2024, 2:09 PM EST) -- SAN FRANCISCO — A panel of the Ninth Circuit U.S. Court of Appeals in an unpublished opinion upheld a California federal judge’s dismissal of a putative class complaint brought by investors against a biopharmaceutical company, agreeing with the judge’s finding that the investors did not adequately plead falsity to back their claim that the company misled investors about the efficacy of a gene therapy drug....